Who Exports Ranitidine from India — 248 Suppliers Behind a $12.6M Market
India's ranitidine export market is supplied by 248 active exporters who collectively shipped $12.6M across 1,996 shipments. COMBITIC GLOBAL CAPLET PRIVATE LIMITED leads with a 21.4% market share, followed by EMCURE PHARMACEUTICALS LIMITED and LINCOLN PHARMACEUTICALS LTD. The top 5 suppliers together control 54.2% of total export value, reflecting a moderately competitive market structure.
Top Ranitidine Exporters from India — Ranked by Export Value
COMBITIC GLOBAL CAPLET PRIVATE LIMITED is the leading ranitidine exporter from India, holding a 21.4% share of the $12.6M market across 1,996 shipments from 248 exporters. The top 5 suppliers — COMBITIC GLOBAL CAPLET PRIVATE LIMITED, EMCURE PHARMACEUTICALS LIMITED, LINCOLN PHARMACEUTICALS LTD, CADILA PHARMACEUTICALS LIMITED, AGILE MEDLINK — collectively control 54.2% of total export value, indicating a moderately concentrated market. Individual shares are: COMBITIC GLOBAL CAPLET PRIVATE LIMITED (21.4%), EMCURE PHARMACEUTICALS LIMITED (17.5%), LINCOLN PHARMACEUTICALS LTD (7.2%), CADILA PHARMACEUTICALS LIMITED (4.5%), AGILE MEDLINK (3.6%).
Top Ranitidine Exporters from India
Ranked by export value · 248 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | COMBITIC GLOBAL CAPLET PRIVATE LIMITED RANITIDINE HYDROCHLORIDE TABLETS IP 150 | $2.7M | 3 | 21.4% |
| 2 | EMCURE PHARMACEUTICALS LIMITED MAR-RANITIDINE TABLETS 150MG 500T CAMAR RANITIDINE TABLETS 150MG 500T CAMAR-RANITIDINE TABLETS 150MG 500T CA,BA | $2.2M | 1 | 17.5% |
| 3 | LINCOLN PHARMACEUTICALS LTD RANITIDINE TABLETS USP USP (RANTICO-150 TABLETS,RANITIDINE HYDROCHLORANTICO-150 TABLETS,RANITIDINE HYDROCHLORIDE B.P. 150MG, | $910.5K | 1 | 7.2% |
| 4 | CADILA PHARMACEUTICALS LIMITED RANITIDINE INJECTION BP 25 MG/2 ML AMPO600,000 AMPOULES RANITIDINE INJECTION BP 25MG/ML AMPOULE | $571.5K | 5 | 4.5% |
| 5 | AGILE MEDLINK RANITIDINE TABLETS BP 300 MG, 10X10 TABSGASTROCAD RANITIDINE TABLET 300MG B | $449.7K | 1 | 3.6% |
| 6 | CAPLIN POINT LABORATORIES LIMITED | $411.4K | 2 | 3.3% |
| 7 | ARAVIS PHARMACEUTICALS RANITIDINE TABLETS USP USP (RANTICO-150 TABLETS,RANITIDINE HYDROCHLORANTICO-150 TABLETS,RANITIDINE HYDROCHLORIDE B.P. 150MG, | $382.6K | 1 | 3.0% |
| 8 | STRIDES PHARMA SCIENCE LIMITED ZANTAC RANITIDINE TABLETS 300MGZANTAC RANITIDINE TABLETS 150MG | $322.7K | 1 | 2.6% |
| 9 | BRAWN LABORATORIES LIMITED RANITIDINE TABLETS USP USP (RANTICO-150 TABLETS,RANITIDINE HYDROCHLORANTICO-150 TABLETS,RANITIDINE HYDROCHLORIDE B.P. 150MG, | $313.1K | 4 | 2.5% |
| 10 | UMEDICA LABORATORIES PRIVATE LIMITED RANITIDINE TABLETS USP USP (RANTICO-150 TABLETS,RANITIDINE HYDROCHLORANTICO-150 TABLETS,RANITIDINE HYDROCHLORIDE B.P. 150MG, | $282.0K | 5 | 2.2% |
| 11 | VKT PHARMA PRIVATE LIMITED MAR-RANITIDINE TABLETS 150MG 500T CAMAR RANITIDINE TABLETS 150MG 500T CAMAR-RANITIDINE TABLETS 150MG 500T CA,BA | $216.8K | 1 | 1.7% |
| 12 | AMN LIFE PRIVATE LIMITED RANITIDINE TABLETS USP USP (RANTICO-150 TABLETS,RANITIDINE HYDROCHLORANTICO-150 TABLETS,RANITIDINE HYDROCHLORIDE B.P. 150MG, | $195.9K | 1 | 1.6% |
| 13 | EURO LIFECARE PRIVATE LIMITED RANITIDINE TABLET 150MG RANITIDINE TABLET BPRANITIDINE TABLETS USP 300MGCHYGOZZY RANITIDINE TABLETS OTHER AS PER INV | $191.5K | 1 | 1.5% |
| 14 | NEON LABORATORIES LIMITED ENTAC 105,000 AMPOULES RANITIDINE HYDROC | $171.4K | 2 | 1.4% |
| 15 | BALAXI PHARMACEUTICALS LIMITED RANITIDINE 300 MG COATED TABLETS GSTIN-RANITIDINE 150 MG COATED TABLETS GSTIN- | $171.1K | 1 | 1.4% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Ranitidine exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Emcure Pharmaceuticals Limited | Warning Letter, August 20 | Unknown | Unknown | Not verified | FDA cited repeat CGMP violations at Hinjawadi facility. |
| Cadila Pharmaceuticals Limited | Warning Letter, December | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP violations. |
| Strides Pharma Science Limited | Warning Letter, July 2019 | Unknown | Unknown | Not verified | FDA cited CGMP and data integrity violations. |
| Indoco Remedies Limited | Warning Letter, July 2019 | Unknown | Unknown | Not verified | FDA cited CGMP and data integrity violations. |
| Aurobindo Pharma Limited | Warning Letter, June 2019 | Unknown | Unknown | Not verified | FDA cited CGMP violations. |
| Dr. Reddy's Laboratories Limited | Warning Letter, November | Unknown | Unknown | Not verified | FDA cited CGMP violations. |
| Wockhardt Limited | Warning Letter, August 20 | Unknown | Unknown | Not verified | FDA cited CGMP violations. |
| Lupin Limited | Warning Letter, March 201 | Unknown | Unknown | Not verified | FDA cited CGMP violations. |
TransData Nexus reviewed the regulatory standing of 8 leading Ranitidine exporters from India. 0 hold US FDA facility approvals, 0 maintain WHO-GMP certification, and 0 are EU GMP compliant. 8 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Ranitidine sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal center for pharmaceutical manufacturing. The city contributes approximately 40% of the country's bulk drug production, underscoring its significance in the pharmaceutical sector. The establishment of Hyderabad Pharma City, envisioned as the world's largest integrated pharmaceutical hub, further cements the city's role in bulk drug manufacturing.
The presence of numerous pharmaceutical companies in Hyderabad, including major players like Dr. Reddy's Laboratories and Aurobindo Pharma, facilitates the large-scale production of active pharmaceutical ingredients (APIs) such as Ranitidine. This concentration of manufacturers ensures a robust supply chain for bulk drugs.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat accounts for 33% of India's drug manufacturing and 28% of drug exports, with Ahmedabad and Vadodara being central to this output.
Vadodara, in particular, hosts Alembic Pharmaceuticals, one of India's oldest pharmaceutical companies, established in 1907. The city's pharmaceutical landscape includes a mix of large-scale manufacturers and smaller enterprises, contributing to a diverse production capacity for formulations like Ranitidine.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a critical export gateway for India's pharmaceutical products. Mumbai's strategic coastal location and well-developed port infrastructure facilitate efficient international distribution. The region is home to several pharmaceutical companies that leverage this logistical advantage to export formulations, including Ranitidine, to global markets.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives offered by the government. These incentives have attracted numerous pharmaceutical companies to set up manufacturing units, contributing to the production of various drugs, including Ranitidine.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Leverage Bulk Drug Production: Utilize Hyderabad's capacity for bulk drug manufacturing to source APIs like Ranitidine efficiently.
- Capitalize on Formulation Expertise: Partner with companies in the Ahmedabad-Vadodara region for high-quality Ranitidine formulations.
- Optimize Export Logistics: Collaborate with manufacturers in the Mumbai-Thane-Raigad area to streamline international distribution channels.
By strategically engaging with these pharmaceutical clusters, TransData Nexus can enhance its supply chain resilience and ensure a steady supply of Ranitidine to meet global demand.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Ranitidine exporters from India
EMCURE PHARMACEUTICALS LIMITED — India's DTAB recommends new safety study for Ranitidine
The Drugs Technical Advisory Board (DTAB) advised the Indian Council of Medical Research (ICMR) to conduct a detailed study evaluating the safety risks associated with NDMA impurities in Ranitidine. - IMPACT: Potential regulatory scrutiny may affect Ranitidine production and export.
Impact: Potential regulatory scrutiny may affect Ranitidine production and export.
LINCOLN PHARMACEUTICALS LTD — CDSCO directs monitoring of NDMA levels in Ranitidine
The Central Drugs Standard Control Organisation (CDSCO) instructed state regulators to ensure manufacturers monitor NDMA levels in Ranitidine products. - IMPACT: Increased compliance requirements may influence export operations.
Impact: Increased compliance requirements may influence export operations.
CADILA PHARMACEUTICALS LIMITED — Reformulated Ranitidine receives regulatory approval
The U.S. FDA approved reformulated Ranitidine tablets, marking the reintroduction of this H₂ receptor antagonist following extensive safety assessments. - IMPACT: Approval may boost Ranitidine exports to regulated markets.
Impact: Approval may boost Ranitidine exports to regulated markets.
Common Questions — Ranitidine Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which ranitidine supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, COMBITIC GLOBAL CAPLET PRIVATE LIMITED leads with 68 recorded shipments worth $2.7M. EMCURE PHARMACEUTICALS LIMITED (71 shipments) and LINCOLN PHARMACEUTICALS LTD (3 shipments) are also established high-volume exporters.
Q How many ranitidine manufacturers are there in India?
India has 248 active ranitidine exporters with a combined export market of $12.6M across 1,996 shipments to 104 countries. The top 5 suppliers hold 54.2% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for ranitidine from India?
Average FOB unit price: $1.61 per unit, ranging from $0.01 to $189.24. Average shipment value: $6.3K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 248 verified Indian exporters of Ranitidine ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,996 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 104 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,996 Verified Shipments
248 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists